Myocarditis development after COVID-19 vaccination in an immunodeficient case

Özdemir, Öner; Şeker, Elif Dilara; DİKİCİ, Ümmügülsüm; Güneş, Muhammed

doi:10.1016/j.imlet.2023.06.001

Cited by 5 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, there were no cases of anaphylaxis or vaccine-induced myocarditis in the cohort, though this does not rule out the occurrence. Myocarditis has been reported following a third mRNA vaccination in a 17-year-old male with CVID, for instance, and anaphylaxis would certainly be expected to occur in a minority of patients [ 27 ].…”

Section: Discussionmentioning

confidence: 99%

COVID-19 Vaccination in Patients with Inborn Errors of Immunity Reduces Hospitalization and Critical Care Needs Related to COVID-19: a USIDNET Report

McDonnell,

Cousins,

Younger

et al. 2024

J Clin Immunol

View full text Add to dashboard Cite

Background The CDC and ACIP recommend COVID-19 vaccination for patients with inborn errors of immunity (IEI). Not much is known about vaccine safety in IEI, and whether vaccination attenuates infection severity in IEI. Objective To estimate COVID-19 vaccination safety and examine effect on outcomes in patients with IEI. Methods We built a secure registry database in conjunction with the US Immunodeficiency Network to examine vaccination frequency and indicators of safety and effectiveness in IEI patients. The registry opened on January 1, 2022, and closed on August 19, 2022. Results Physicians entered data on 1245 patients from 24 countries. The most common diagnoses were antibody deficiencies (63.7%). At least one COVID-19 vaccine was administered to 806 patients (64.7%), and 216 patients received vaccination prior to the development of COVID-19. The most common vaccines administered were mRNA-based (84.0%). Seventeen patients were reported to seek outpatient clinic or emergency room care for a vaccine-related complication, and one patient was hospitalized for symptomatic anemia. Eight hundred twenty-three patients (66.1%) experienced COVID-19 infection. Of these, 156 patients required hospitalization (19.0%), 47 required ICU care (5.7%), and 28 died (3.4%). Rates of hospitalization (9.3% versus 24.4%, p < 0.001), ICU admission (2.8% versus 7.6%, p = 0.013), and death (2.3% versus 4.3%, p = 0.202) in patients who had COVID-19 were lower in patients who received vaccination prior to infection. In adjusted logistic regression analysis, not having at least one COVID-19 vaccine significantly increased the odds of hospitalization and ICU admission. Conclusion Vaccination for COVID-19 in the IEI population appears safe and attenuates COVID-19 severity.

show abstract

Section: Discussionmentioning

confidence: 99%

COVID-19 Vaccination in Patients with Inborn Errors of Immunity Reduces Hospitalization and Critical Care Needs Related to COVID-19: a USIDNET Report

McDonnell,

Cousins,

Younger

et al. 2024

J Clin Immunol

View full text Add to dashboard Cite

show abstract

“…COVID-19 has also been linked to an elevated risk of blood clots [18] and abnormal blood clotting [19], leading to conditions like deep vein thrombosis (DVT) [20], pulmonary embolism (PE) [21], and disseminated intravascular coagulation (DIC) [22]. Some individuals infected with SARS-CoV-2 may develop myocarditis [23], an inflammatory condition affecting the heart muscle [24]. Furthermore, COVID-19 can contribute to various cardiac complications [25], including arrhythmias [26], heart failure [25], and acute coronary syndromes [27].…”

mentioning

confidence: 99%

Novel polymer-based hydrogels of recent research in drug delivery for disease treatment related to SARS-CoV-2 virus

Hoc Thang,

Van Phuc,

Nhi

et al. 2024

Express Polym. Lett.

View full text Add to dashboard Cite

The COVID-19 pandemic has presented an array of challenges and given rise to a spectrum of diseases and health issues [1]. Foremost among the challenges of the pandemic is the swift transmission of the SARS-CoV-2 virus [2]. Strategies to curb transmission encompass extensive vaccination campaigns [3], the implementation of public health measures like mask-wearing [4] and social distancing [4], and the promotion of hygiene practices such as frequent handwashing [5]. The SARS-CoV-2 virus, which causes COVID-19, primarily targets the respiratory system [6]. However, it can also precipitate various complications and impact other organs and bodily systems [7]. COVID-19, an abbreviation for Coronavirus Disease 2019, is the ailment brought about by the SARS-CoV-2 virus [8]. It manifests as a broad spectrum of symptoms, spanning from mild to severe respiratory ailments [9]. Common symptoms include fever, cough, shortness of breath, fatigue, loss of taste or smell, and body aches [10]. In severe instances, it can progress to pneumonia and acute

show abstract

Immune-globulin/tozinameran

2023

Reactions Weekly

View full text Add to dashboard Cite

Myocarditis development after COVID-19 vaccination in an immunodeficient case

Cited by 5 publications

References 12 publications

COVID-19 Vaccination in Patients with Inborn Errors of Immunity Reduces Hospitalization and Critical Care Needs Related to COVID-19: a USIDNET Report

COVID-19 Vaccination in Patients with Inborn Errors of Immunity Reduces Hospitalization and Critical Care Needs Related to COVID-19: a USIDNET Report

Novel polymer-based hydrogels of recent research in drug delivery for disease treatment related to SARS-CoV-2 virus

Immune-globulin/tozinameran

Contact Info

Product

Resources

About